Compounded vials require self-measurement, which adds dosing-error risk not present with fixed-dose pens.
Many compounded products come as multi-dose vials where you draw the dose yourself. Concentrations vary by pharmacy, so “units” on a syringe don’t map cleanly to milligrams. A mismatch between the prescribed dose and the vial concentration can cause accidental overdosing. If unsure, confirm with the prescriber or pharmacy before injecting.
| What to know |
|---|
| Compounded vials require self-measurement, which adds dosing-error risk not present with fixed-dose pens. |
| Many compounded products come as multi-dose vials where you draw the dose yourself. |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.